Wavegate Corporation, based in Lake Charles, Louisiana, develops neuromodulation technology for chronic pain centered on its Ellipse™ spinal cord stimulator. Ellipse uses optical reflectometry and the company’s StimuLux™ technology to provide closed-loop adaptive modulation that adjusts stimulation in real time based on spinal cord movement. The platform supports both paresthesia-based and paresthesia-free neuromodulation to help maintain consistent pain relief across a range of patient activities. Ellipse has received FDA Breakthrough Device designation and Wavegate reported successful first-in-human data validating its clinical promise. The company plans to use the Series A proceeds to accelerate R&D, expand clinical trials, and prepare for regulatory approvals en route to commercialization. Wavegate announced a $26 million Series A financing on Dec. 10, 2024.

Total raised

$26M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2024